Recent advances in targeting the urokinase plasminogen activator with nanotherapeutics

AA Kumar, KL Vine, M Ranson - Molecular Pharmaceutics, 2023 - ACS Publications
The aberrant proteolytic landscape of the tumor microenvironment is a key contributor of
cancer progression. Overexpression of urokinase plasminogen activator (uPA) and/or its …

Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review

R Camedda, V Frantellizzi, R Danieli… - Expert Review of …, 2024 - Taylor & Francis
Introduction To provide an overview of the available literature data on clinical applications of
positron emission tomography (PET) targeting the urokinase-type plasminogen activator …

[HTML][HTML] Potential of UPAR, Αvβ6 integrin, and tissue factor as targets for molecular imaging of oral squamous cell carcinoma: evaluation of nine targets in primary …

M Lawaetz, A Christensen, K Juhl, K Karnov… - International Journal of …, 2023 - mdpi.com
No clinically approved tumor-specific imaging agents for head and neck cancer are currently
available. The identification of biomarkers with a high and homogenous expression in tumor …

[HTML][HTML] Side-by-side comparison of uPAR-targeting optical imaging antibodies and antibody fragments for fluorescence-guided surgery of solid tumors

VM Baart, L van Manen, SS Bhairosingh… - Molecular Imaging and …, 2021 - Springer
Purpose Radical resection is paramount for curative oncological surgery. Fluorescence-
guided surgery (FGS) aids in intraoperative identification of tumor-positive resection …

[HTML][HTML] Targeted imaging of uPAR expression in vivo with cyclic AE105 variants

JM Leth, EA Newcombe, AL Grønnemose… - Scientific Reports, 2023 - nature.com
A comprehensive literature reports on the correlation between elevated levels of urokinase-
type plasminogen activator receptor (uPAR) and the severity of diseases with chronic …

[HTML][HTML] Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [64Cu]Cu-DOTA-AE105 uPAR-PET/CT in Patient-Derived Xenograft Models of Oral …

M Lawaetz, T Binderup, A Christensen, K Juhl… - Molecular Imaging and …, 2023 - Springer
Abstract Purpose [64Cu] Cu-DOTA-AE105 urokinase-type plasminogen activator receptor
(uPAR)-PET/CT is a novel and promising imaging modality for cancer visualization, although …

[HTML][HTML] Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective …

M Lawaetz, A Christensen, K Juhl, G Lelkaitis… - Diagnostics, 2023 - mdpi.com
The detection of lymph node metastases is a major challenge in oral and oropharyngeal
squamous cell carcinoma (OSCC and OPSCC). 68Ga-NOTA-AE105 is a novel positron …

[HTML][HTML] uPAR (PLAUR) Marks Two Intra-Tumoral Subtypes of Glioblastoma: Insights from Single-Cell RNA Sequencing

Y He, KBV Døssing, M Rossing, FO Bagger… - International Journal of …, 2024 - mdpi.com
Urokinase plasminogen activator receptor (uPAR) encoded by the PLAUR gene is known as
a clinical marker for cell invasiveness in glioblastoma multiforme (GBM). It is additionally …

[HTML][HTML] Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients

LM Risør, T Binderup, MØ Fosbøl, KF Andersen… - Scientific Reports, 2022 - nature.com
Strong prognostic biomarkers are lacking regarding the stratification of treatment and
surveillance regimens in head and neck squamous cell carcinoma (HNSCC). The study …

[HTML][HTML] Human antibody VH domains targeting uPAR as candidate therapeutics for cancers

X Chu, W Li, MG Hines, I Lyakhov, JW Mellors… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
The high expression of uPAR has been linked to tumor progression, invasion, and
metastasis in several types of cancer. Such overexpression of uPAR makes it a potential …